Mesothelioma Articles

Phase II Study of Alanosine in Patients With Methylthioadenosine Phosphorylase (MTAP)-Deficient Cancer

Date First Published: 2003-05-23

BASIC STUDY INFORMATION

PATIENT ABSTRACT:

Rationale:
Drugs used in chemotherapy such as alanosine use different ways to stop tumor cells from dividing so they stop growing or die.

Purpose:
Phase II trial to study the effectiveness of alanosine in treating patients who have soft tissue sarcoma, sarcoma of the bone, mesothelioma, non-small cell lung cancer, or pancreatic cancer.

Eligibility:
 •At least 18 years old (at least 13 years old for patients who have osteosarcoma)
 •Measurable disease
 •More than 6 weeks since chemotherapy
 •At least 4 weeks since radiation therapy to the brain
 •At least 4 weeks since surgery

Treatment Intervention:
Patients will receive a 5-day continuous infusion of alanosine every 3 weeks. Treatment may be repeated for up to nine courses. Patients will be evaluated at 4 weeks.

Disclaimer:
This abstract is intended to give a brief overview of this clinical trial. To help determine whether the trial is appropriate for an individual, selected major eligibility criteria are listed above. To obtain more details related to trial eligibility and the treatment plan, please see the Health Professional abstract of this clinical trial. Information about ongoing clinical trials is available from the NCI Cancer.gov Web site.

STUDY LEAD ORGANIZATIONS:
 Memorial Sloan-Kettering Cancer Center
 Lee M. Krug, MD, Protocol chair
 Ph: 212-639-8420

STUDY SITES AND CONTACTS

U.S.A.

New York
 Memorial Sloan-Kettering Cancer Center
  Lee M. Krug, MD
  Ph: 212-639-8420

St. Vincents Comprehensive Cancer Center
 Gerald Rosen, MD
 Ph: 212-367-1729
 gerald.rosen@verizon.net

Source: Cancer.gov

MIRG.org 1-888-802-6376 e-mail

www.MIRG.org • Site Map • About Us • Contact Us • Links • Disclaimer